EnteroBiotix
PrivateLast Round
Seed Round
Mar 30, 2026
Total Funding Raised
$59.09M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
EnteroBiotix operates in Healthcare & Life Sciences and is based in Glasgow. Its latest recorded funding round was a Series B round in April 2024.
EnteroBiotix is a biotechnology company that develops microbiome-modulating drugs aimed at restoring health and preventing bacterial infections through tailored high-diversity microbial therapeutics for patients with serious unmet medical needs.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
EnteroBiotix Comparables
Compare EnteroBiotix with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Microbiotica | 85% | |
| BiomeBank | 83% | |
| Human Biome S.A. | 82% |
For institutional investors. Book with your work email.
EnteroBiotix Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Seed Round | Mar 30, 2026 | ||||
| Series B | Apr 4, 2024 | ||||
| Series A | Sep 7, 2021 | ||||
| Seed | May 29, 2019 | ||||
| Seed | Jun 21, 2017 | ||||
Grant | Jun 21, 2017 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
EnteroBiotix Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| University of Aberdeen | Seed |
| Gabriel Investments Ltd | Seed |
| Kineticos Ventures | Series A, Series B |
| Equity Gap | Series B, Seed |
| Scottish EDGE | Grant |
| Scottish National Investment Bank | Seed, Series A, Series B, Seed Round |
| Barwell Plc | Seed |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 20, 2026
Monthly visitors grew 62% MoM, reaching 3.7K.
- Jul 28, 2026
Monthly visitors grew 392% MoM, from 460 to 2.3K.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- hiresNov 2, 2026
EnteroBiotix Ltd appoints former GSK and Rhythm Pharmaceuticals Chief Medical Officer Dr Murray Stewart to its Board of Directors on Nov 3rd '26.
For institutional investors. Book with your work email.
EnteroBiotix Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about EnteroBiotix's valuation, stock price, and market status.
Is EnteroBiotix a public or private company?
EnteroBiotix is a private company.
What is the current stock price of EnteroBiotix?
EnteroBiotix is a private company, so its shares have no public market price. Caplight tracks EnteroBiotix's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is EnteroBiotix worth (valuation)?
Valuation information for EnteroBiotix is not publicly available.
Can I buy EnteroBiotix stock?
EnteroBiotix shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was EnteroBiotix's last funding round?
EnteroBiotix's most recent funding round was Seed Round on March 30, 2026.
Who are the main investors in EnteroBiotix?
Key investors in EnteroBiotix include Equity Gap, Scottish National Investment Bank.
Will EnteroBiotix IPO soon?
No public IPO plans have been announced for EnteroBiotix.
How can I track EnteroBiotix secondary market activity?
Caplight tracks bids, offers, and trades in EnteroBiotix's shares on secondary markets.